Welcome to our dedicated page for Compass Pathways Plc news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways Plc stock.
Compass Pathways plc (Nasdaq: CMPS) generates frequent news as it advances COMP360, its investigational synthetic psilocybin treatment, through late-stage clinical development for serious mental health conditions. The company focuses on treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), and its updates often highlight progress in these programs, regulatory interactions, and collaborations related to potential delivery models.
News items for CMPS commonly cover clinical trial milestones, such as Phase 3 results in TRD and the design and initiation of late-stage trials in PTSD. For example, Compass has reported achievement of the primary endpoint in its COMP005 Phase 3 trial in TRD and the U.S. Food and Drug Administration’s acceptance of an Investigational New Drug application for COMP360 in PTSD, enabling a Phase 2b/3 trial. Publications of clinical data in peer-reviewed journals, including results from a Phase 2 PTSD study, are also featured.
Investors and observers can also expect announcements about strategic collaborations with healthcare organizations and clinic networks. These collaborations, including those with Radial Health, Greenbrook Mental Wellness Centers, Hackensack Meridian Health, Reliant Medical Group, Journey Clinical, Mindful Health Solutions, and HealthPort, are described as helping to inform how investigational COMP360 treatment might be integrated into various care settings if approved.
Additional CMPS news includes financial results, participation in investor and healthcare conferences, and corporate governance developments such as board appointments. Together, these updates provide context on Compass Pathways’ clinical, regulatory, and operational progress as it pursues evidence-based innovation in mental health. Readers interested in CMPS can use this news feed to follow key developments in the company’s COMP360 programs and broader mental health biotechnology strategy.
Summary not available.
Summary not available.
Summary not available.
The global psychedelic drugs market witnessed growth, expanding from
COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company, will present at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 9:30 am ET. The presentation will be accessible via a live audio webcast on the company’s website, with a replay available for 30 days afterward.
COMPASS focuses on accelerating patient access to innovative mental health solutions, particularly through its psilocybin therapy, COMP360, which has received Breakthrough Therapy designation from the FDA and ILAP designation in the UK for treatment-resistant depression (TRD). The company is conducting the largest-ever randomized, controlled, double-blind psilocybin therapy clinical program for TRD, following a successful phase 2b study that demonstrated significant improvements in depressive symptoms.
COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company, announced management participation in three significant events. These include:
- Cowen 43rd Annual Health Care Conference on March 6, 2023, at 12:50 pm ET
- Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 10:00 am ET
- Loop Capital Conference on March 14, 2023
Live webcasts will be available on their investors’ page, with replays for 30 days post-event. COMPASS focuses on providing innovative treatment options, notably their psilocybin therapy COMP360, which has been designated as a Breakthrough Therapy by the FDA and targets treatment-resistant depression.
COMPASS Pathways plc (Nasdaq: CMPS) has made significant progress with its COMP360 psilocybin therapy. The Phase 3 pivotal program for treatment-resistant depression (TRD) includes two trials, with the first one (COMP 005) expecting data by summer 2024 and the second (COMP 006) by mid-2025. The company's cash position stands at $143.2 million as of December 31, 2022, despite a net loss of $91.5 million for the year. R&D expenses increased to $65.1 million for 2022, reflecting ongoing clinical investigations. Financial guidance for Q1 2023 indicates an operating cash outflow of $24-$32 million.
COMPASS Pathways (Nasdaq: CMPS) announced its plans to release financial results for Q4 and year-end 2022 on February 28, 2023. Alongside the financial results, the company will update investors on recent business developments. A conference call will be held at 8:00 AM ET (1:00 PM UK), where the management team will discuss these updates. The call can be accessed by pre-registering, and a live webcast will also be available on the company's website. COMPASS specializes in mental health innovation, focusing on psilocybin therapy with its proprietary formulation, COMP360, designated as a Breakthrough Therapy by the FDA.
COMPASS Pathways (Nasdaq: CMPS) announced promising results from a recent study on COMP360 psilocybin therapy. In an exploratory open-label study for type II bipolar disorder, 86% of participants achieved remission within three months after a single 25mg dose. Additionally, data from a phase 2b trial for treatment-resistant depression (TRD) was presented, highlighting the correlation between positive psychedelic experiences and reduced depression severity. The therapy has received FDA Breakthrough Therapy designation, signaling its potential in mental health treatment.
LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) will host a fireside chat at the Evercore ISI HealthCONx Conference at 9:15 am ET on November 30, 2022. A live audio webcast will be available on the COMPASS website's Events page, with a replay accessible for 30 days post-event. The company, focused on mental health innovation, is developing psilocybin therapy with its proprietary formulation, COMP360, which has received Breakthrough Therapy designation from the FDA for treatment-resistant depression. COMPASS also conducts trials for PTSD and anorexia nervosa.